



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ABT-107

Cat. No.:	HY-108038		
CAS No.:	855291-54-2		
Molecular Formula:	C ₁₉ H ₂₀ N ₄ O		
Molecular Weight:	320.39		
Target:	nAChR		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (312.12 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		3.1212 mL	15.6060 mL	31.2120 mL
		5 mM		0.6242 mL	3.1212 mL	6.2424 mL
		10 mM		0.3121 mL	1.5606 mL	3.1212 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions ^{[1][2]} .
In Vivo	ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally, 100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly, 100%), and good CNS penetration in rodents with a brain/plasma ratio of 1 ^[1] . ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB ^[1] .

ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S⁹-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice^[1].
 ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats (male Sprague-Dawley; 350-380 g b.wt.) ^[1] .
Dosage:	1, 3 µmol/kg.
Administration:	I.P. daily for 3 consecutive days.
Result:	Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration. Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior.
Animal Model:	Female TAPP (and wild-type littermates) mice ^[1] .
Dosage:	1 mg/kg.
Administration:	Continuous subcutaneous infusion for 2 weeks.
Result:	Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice.

REFERENCES

- [1]. R Scott Bitner, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86.
- [2]. Tanuja Bordia, et al. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA